Albireo Pharma, Inc.
ALBO · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.52 | -0.17 | -0.09 | -0.24 |
| FCF Yield | -24.13% | -16.86% | -16.91% | -9.36% |
| EV / EBITDA | -10.57 | -3.72 | -3.22 | -3.26 |
| Quality | ||||
| ROIC | -213.94% | -40.88% | -47.81% | -21.96% |
| Gross Margin | 96.66% | 100.00% | 77.07% | 100.00% |
| Cash Conversion Ratio | 3.16 | 0.94 | 0.84 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 61.49% | -13.28% | 2,027.97% | 3.88% |
| Free Cash Flow Growth | -6.84% | -89.13% | -99.01% | 3.22% |
| Safety | ||||
| Net Debt / EBITDA | 12.01 | 2.52 | 2.30 | 4.33 |
| Interest Coverage | -8.86 | -8.47 | -11.54 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 6.99 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,672.29 | 0.00 | -790.28 | 83.51 |